A Unified 3D Generative Model for Synthesizable Structure-Based Drug Design
Traditional screening-based drug discovery is inherently limited by the astronomical scale of the chemical space. Generative modelling offers a compelling alternative to the classical search paradigm and enables rational, bottom-up design of novel and target-specific small molecules. However, its impact has been hampered by challenges in synthetic accessibility of the designed compounds and lack…
A new generative framework called LDDM (Large Drug Discovery Model) has been introduced for drug design. This method addresses limitations in traditional screening-based drug discovery by providing a bottom-up, rational design approach for novel, target-specific small molecules. LDDM supports various tasks such as constrained and unconstrained docking, fragment linking and growing, and de novo design.
The researchers have also developed a programmable design algorithm that can accurately create synthetically accessible compounds meeting specific objectives. To validate their approach, they experimentally tested the designed or optimized ligands for five therapeutically relevant protein targets. In each instance, LDDM demonstrated high success rates, enabling the identification of molecules with confirmed binding affinity while synthesizing only a small number of generated compounds.
Upon successful synthesis, the best designs were characterized through NMR spectroscopy and X-ray crystallography. These techniques confirmed the high prediction accuracy of LDDM's designs. In summary, LDDM offers a scalable and flexible platform for rapidly and tailoredly designing small molecules and non-natural peptides for therapeutic applications.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
